David Berg

David Berg was the Director and Cofounder with Lois Hill Berg, of HEMEX Laboratories before he retired and sold it. He discovered that approximately 85% of chronic fatigue syndrome patients had hypercoagulation, i.e., the tendency for blood to clot too much, possibly from lower serum levels. He reported that a significant percentage of people obtain remission from anti-coagulation therapy combined with anti-infection therapy.

Talks and Interviews

 * Treatment protocol
 * Aug 29, 1999, Radio Interview Transcript
 * Town Hall Talk #1
 * Town Hall Talk #3
 * Town Hall Talk #4
 * 1999 AHMF Meeting

Notable studies

 * 2001, Hypercoaguable State Associated with Active Human Herpesvirus-6 (HHV-6) Viremia in Patients with Chronic Fatigue Syndrome"'Summary - Objectives: A subset of patients with Chronic Fatigue Syndrome (CFS) have been found to be hypercoaguable in small previous studies. We wanted to analyze the incidence of a hypercoaguable state and assess hereditary hypercoaguable risk factors in a group of patients with known CFS and HHV-6 viremia. Methods: Thirty patients diagnosed with CFS that had at least one prior positive blood culture for active HHV-6 by rapid culture method were studied. A hypercoaguable panel was obtained to assess activation of coagulation. Two or more positive tests were determined to represent activation of coagulation. Hereditary thrombosis risk panels were also performed which included eight different genetic tests to assess hereditary abnormalities. Results: Twenty-four of thirty (80%) patients had a hypercoaguable state, thus activation of coagulation. Twenty-five of thirty (83%) of patients had a hereditary abnormality. Conclusions: CFS patients with active HHV-6 infection (viremia) have activation of coagulation and are hypercoaguable. Hereditary thrombosis risk factors are very prevalent in these patients. These hereditary abnormalities increase the hypercoaguable tendencies. The hypercoaguable state associated with active HHV-6 infection may be a significant contributing factor to the symptoms seen in CFS patients.'"